All In Biotech

NDA 022000 · Takeda Pharms USA

Lialda

Mesalamine · Oral · Aminosalicylate

Orphan

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Jan 16, 2007

Approved uses

3

Original approval plus efficacy supplements

Registered trials

188

77 Phase 3, 14 recruiting

FAERS reports

36,767

29,039 serious, 2,144 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

LIALDA ® is indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg. LIALDA is an aminosalicylate indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. ( 1 ) treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg. ( 1 )

Mechanism: The mechanism of action of mesalamine is not fully understood, but it appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LIALDA · MESALAMINE 1.2GM · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mesalamine" as an intervention, any sponsor and status, largest first.

All 188 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use6,841
  • drug ineffective5,388
  • colitis ulcerative5,375
  • condition aggravated3,686
  • diarrhoea3,406
  • haematochezia2,959
  • fatigue2,745
  • abdominal pain2,577
  • headache2,274
  • nausea2,274
  • pyrexia2,151
  • weight decreased2,149

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004106
2005149
2006106
2007165
2008638
2009274
2010367
2011951
2012959
2013638
20141,219
20151,654
20161,455
20171,062
20181,202
20191,226
20201,578
20212,800
20224,468
20234,564
20244,371
20254,286
20262,528

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lialda (Mesalamine)

2024 spending

$7.0M

Beneficiaries

1,214

4,327 claims

Per beneficiary

$5,790

$8.93 per unit

View as table
YearSpending
2020$19,319,747
2021$20,116,023
2022$16,810,574
2023$14,380,281
2024$7,028,945

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 264 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.